BioXcel Therapeutics, Inc. (BTAIQ)

Market Cap	1.34M -97.5%
Revenue (ttm)	742.00K -14.5%
Net Income	-70.86M
EPS	-3.15
Shares Out	31.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,288,291
Open	0.0190
Previous Close	0.0739
Day's Range	0.0190 - 0.0438
52-Week Range	0.0190 - 4.2900
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmede...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 29
• Stock Exchange: OTCMKTS
• Ticker Symbol: BTAIQ

Financial Performance

In 2025, BioXcel Therapeutics's revenue was $642,000, a decrease of -71.67% compared to the previous year's $2.27 million. Losses were -$69.90 million, 17.3% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 8, 2026

Data Sources Report a data error